150 related articles for article (PubMed ID: 2857878)
1. Disappearance of captopril-induced taste disturbance after substitution with angiotensin-converting-enzyme inhibitor HOE 498.
Mauersberger H; Witte PU
Lancet; 1985 Mar; 1(8427):517-8. PubMed ID: 2857878
[No Abstract] [Full Text] [Related]
2. [Immunological effects of captopril and ramipril in patients with hypertension].
Vil'chinskaia MIu; Nasonov EL; Zharova EA; Panfilov VV; Masenko VP; Oshchepkova EV; Beliakova EV
Klin Med (Mosk); 1990 Feb; 68(2):61-4. PubMed ID: 2139910
[TBL] [Abstract][Full Text] [Related]
3. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension.
Witte PU; Walter U
Am J Cardiol; 1987 Apr; 59(10):115D-120D. PubMed ID: 3034018
[TBL] [Abstract][Full Text] [Related]
4. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
Iimura O; Shimamoto K
Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450
[TBL] [Abstract][Full Text] [Related]
5. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
Böhm RO; van Baak MA; Rahn KH
Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
[TBL] [Abstract][Full Text] [Related]
7. Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril.
de Graeff PA; Kingma JH; Dunselman PH; Wesseling H; Lie KI
Am J Cardiol; 1987 Apr; 59(10):164D-170D. PubMed ID: 3034026
[TBL] [Abstract][Full Text] [Related]
8. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.
de Leeuw PW; Lugtenburg PL; van Houten H; Looman JH; Birkenhäger WH
J Cardiovasc Pharmacol; 1985; 7(6):1161-5. PubMed ID: 2418304
[TBL] [Abstract][Full Text] [Related]
9. Influence of the converting enzyme inhibitors Hoe 498, enalapril and captopril on vascular reactivity of isolated arterial preparations.
Schölkens BA; Xiang JZ; Tilly H
Clin Exp Hypertens A; 1984; 6(10-11):1807-13. PubMed ID: 6099766
[No Abstract] [Full Text] [Related]
10. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.
Wenting GJ; Blankestijn PJ; Poldermans D; van Geelen J; Derkx FH; Man in't Veld AJ; Schalekamp MA
Am J Cardiol; 1987 Apr; 59(10):92D-97D. PubMed ID: 3034041
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.
Bünning P
Arzneimittelforschung; 1984; 34(10B):1406-10. PubMed ID: 6097266
[TBL] [Abstract][Full Text] [Related]
12. Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.
Felder K; Witte PU
Arzneimittelforschung; 1984; 34(10B):1452-4. PubMed ID: 6097273
[TBL] [Abstract][Full Text] [Related]
13. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.
Vasmant D; Bender N
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S46-52. PubMed ID: 2483429
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibitors: past, present, and bright future.
Edwards CR; Padfield PL
Lancet; 1985 Jan; 1(8419):30-4. PubMed ID: 2856956
[No Abstract] [Full Text] [Related]
15. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
[TBL] [Abstract][Full Text] [Related]
16. Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems.
Manthey J; Osterziel KJ; Röhrig N; Dietz R; Hackenthal E; Schmidt-Gayk H; Kübler W
Am J Cardiol; 1987 Apr; 59(10):171D-175D. PubMed ID: 2953224
[TBL] [Abstract][Full Text] [Related]
17. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
Bauer B; Lorenz H; Zahlten R
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S70-4. PubMed ID: 2474109
[TBL] [Abstract][Full Text] [Related]
18. Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.
Kaneko Y; Omae T; Yoshinaga K; Iimura O; Inagaki Y; Ishii M; Saruta T; Yamada K; Kumahara Y; Ito K
Am J Cardiol; 1987 Apr; 59(10):86D-91D. PubMed ID: 3034040
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats.
Moursi MG; Ganten D; Lang RE; Unger T
J Hypertens Suppl; 1986 Oct; 4(3):S495-8. PubMed ID: 3023591
[TBL] [Abstract][Full Text] [Related]
20. Short- and long-term effects of ramipril in hypertension.
de Leeuw PW; Birkenhäger WH
Am J Cardiol; 1987 Apr; 59(10):79D-82D. PubMed ID: 3034038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
